Summary
Cannot verify any of the extracted claims against the provided FDA label content because only a section identifier ('12 CLINICAL PHARMACOLOGY') is available with no label text excerpt. Multiple claims attribute specific FDA guidance (including vaccination timing) and include safety assertions that are not supported by the supplied label material.
Category Scores
Accurate Statements
Unsupported Statements
Cosentyx (secukinumab) is a biologic medication that targets interleukin-17A (IL-17A).
Not verifiable: no FDA label text supporting biologic characterization or IL-17A targeting was provided from section 12.
Cosentyx is used to treat psoriatic arthritis.
Not verifiable: no FDA indication text was provided.
Cosentyx is used to treat ankylosing spondylitis.
Not verifiable: no FDA indication text was provided.
Cosentyx is used to treat plaque psoriasis.
Not verifiable: no FDA indication text was provided.
According to the FDA, there is no specific waiting period recommended for starting Cosentyx after vaccination.
Not verifiable: no FDA vaccination guidance text was provided; FDA attribution cannot be confirmed.
The FDA recommends that patients with autoimmune disorders, including those taking biologics like Cosentyx, receive all recommended vaccinations before starting therapy.
Not verifiable: no FDA vaccination recommendation text was provided.
The American Academy of Dermatology (AAD) recommends that patients receiving biologic therapy, including Cosentyx, receive all recommended vaccinations before starting biologic therapy.
External-source claim; no FDA label text was provided to support it.
The AAD notes that patients should wait at least 2-4 weeks after receiving live vaccines before starting biologic therapy.
External-source claim; no FDA label text was provided to support it.
Some experts recommend waiting longer, up to 6-8 weeks, after receiving live vaccines before starting Cosentyx.
External-source/expert claim; no FDA label text was provided to support it.
Premature vaccination can increase the risk of adverse reactions, including anaphylaxis.
Not verifiable: no FDA label safety statement regarding vaccination timing or anaphylaxis risk was provided.
Contradictions
Important Omissions
FDA label content needed to evaluate safety-critical claims (e.g., boxed warnings, contraindications, dosage/administration including vaccination/live vaccine instructions, warnings/precautions, and adverse reactions).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response includes FDA-attributed vaccination timing guidance and an anaphylaxis risk statement without any supporting FDA label excerpts; this prevents verification and could mislead clinical decisions involving vaccination and biologic initiation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Verifiable
Primary Issue
FDA label excerpts necessary to verify the claims were not provided (only '12 CLINICAL PHARMACOLOGY' section identifier). FDA-attributed vaccination timing and safety assertions are therefore unsupported.
Suggested Improvement
Provide the actual FDA label text excerpts for the claims (Indications, Vaccination guidance/precautions, warnings/precautions, adverse reactions, and any contraindications/boxed warnings relevant to vaccination timing). Then re-evaluate each claim strictly against the supplied label text.